Logistics & Transportation

Articles

The new $43M plasmid manufacturing facility will support both clinical and commercial production in the cancer and infectious disease spaces.

CDMO is commissioning third GMP biologics facility in Fremont.

CDMO will be providing high-quality lentiviral vectors for CAR-T therapies.




Location serves as the US flagship for company’s global pharma development network.  




Project—which is expected to double plant’s distribution capacity—will be completed by end of Q3.



Complex to develop cGMP-compliant, commercial-scale plasmid DNA. 



Companies to release variety of options for this sector.

 


Expansion expected to help tackle health issues at a faster rate, company says




Transaction expected to close early this year




Creates Cellular Origins in order to simplify the late-stage development process


